Hyderabad, India – March 12, 2013 – Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and ...

Strong R&D investment, advanced manufacturing technologies, and supportive government policies accelerate global API production growth.Austin, Texas, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Small Molecule ...

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.

The track by which API manufacturing processes are prepared for commercial use is comparable to overlapping integrative process evaluations at commercial scale. This ensures the process is ...

Even when a drug finishes its production in the U.S., its active and inactive components often come from overseas. While pharmaceutical companies have been unveiling plans for new U.S. manufacturing ...

(MENAFN- IMARC Group) Setting up an API Manufacturing facility necessitates a detailed market analysis alongside granular insights into various operational aspects, including unit processes, raw ...

The global high potency API contract manufacturing market, valued at USD 8 billion in 2022, is poised for robust growth, with projections to reach USD 16 billion by 2032. This remarkable expansion, ...

Japan’s pharmaceutical industry is undergoing a period of transformation, and the contract development and manufacturing organization (CDMO) of large molecule active pharmaceutical ingredients (APIs) ...